Effect of KRAS mutations and PD-L1 expression on therapy response in non-small cell lung cancer
- 5 August 2022
- conference paper
- conference paper
- Published by Medicom Medische Uitgeverij BV in Medicom Conference Report ASCO 2022
Abstract
No abstract availableThis publication has 2 references indexed in Scilit:
- KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLCAnnals of Oncology, 2019
- Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trialAnnals of Oncology, 2019